HRS 7058
Alternative Names: HRS-7058Latest Information Update: 14 Jun 2026
At a glance
- Originator Shandong Suncadia Medicine
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer; Solid tumours
Most Recent Events
- 04 Jun 2026 Phase-II clinical trials in Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (unspecified route) (NCT07589569)
- 22 May 2026 Shandong Suncadia Medicine plans a phase III trial for Non small cell lung cancer (Late-stage diseases, metastatic diseases, Second-line or greater therapy) in China in June 2026 (PO) (NCT07601048)
- 15 May 2026 Shandong Suncadia Medicine plans a phase II trial for Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent, Inoperable/Unresectable) in China , (NCT07589569)